Recalibrating sham-relative superiority thresholds in BPH device trials
- 13 August 2026
- journal article
- other
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 559
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- 12-MONTH OUTCOMES FROM A RANDOMIZED, SHAM CONTROLLED STUDY EVALUATING A NOVEL PROSTATIC URETHRAL STENT FOR THE TREATMENT OF BPHJournal of Urology, 2025
- A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in menTranslational Andrology and Urology, 2024
- The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2023
- The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled TrialUrology, 2021
- Pain, placebo, and test of treatment efficacy: a narrative reviewBritish Journal of Anaesthesia, 2019
- Understanding the Minimal Clinically Important Difference (MCID) of Patient‐Reported Outcome MeasuresOtolaryngology–Head and Neck Surgery, 2019
- 24‐month durability after crossover to the prostatic urethral lift from randomised, blinded shamBJU International, 2016
- Clinically and Statistically Significant Changes Seen in Sham Surgery Arms of Randomized, Controlled Benign Prostatic Hyperplasia Surgery TrialsJournal of Urology, 2015
- A Model of Placebo Response in Antidepressant Clinical TrialsAmerican Journal of Psychiatry, 2013